Octahedron Drug Research 5 (2024) 1-12

ISSN: 2812-6351
Online ISSN: 2812-636X

OCTAHEDRON
Drug Research
Vol. 5

Review Article

Navigating the intricacies of breast cancer histological terrain and the efficacy of paclitaxel as a chemotherapeutic arsenal

Ahmed T. M. Elshennawy*

*Department of Anatomy, Faculty of Medicine, Al-Baha University, Albaha, Saudi Arabia
Correspondence: ahmadelshennawy@yahoo.com; ahmadelshennawy@gmail.com; Tel: +966539393160

ARTICLE INFO

Article history :
Received 2 February 2024
Received in revised form
4 February 2024
Accepted 5 February 2023
Available online 1 June 2024

Keywords: Breast Cancer; Histology; Histopathology; Paclitaxel

© 2024 by the authors; licensee Port Said University, Egypt. This open-access article is distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

Breast cancer, a multifaceted and heterogeneous malady, invites scrutiny into its microscopic intricacies, where the landscape of cellular interactions orchestrates disease progression and therapeutic responses. This comprehensive review intricately explores the cellular terrain, unraveling the intricate web of signaling pathways, genetic variations, and microenvironmental dynamics shaping the pathogenesis of breast cancer. A central focus of this exploration is the in-depth analysis of the chemotherapeutic powerhouse, Paclitaxel, which stands as a stalwart in the arsenal against breast cancer. The molecular mechanisms governing Paclitaxel's actions take a central stage, providing a detailed examination of its impact on microtubule dynamics and the pivotal cellular processes essential for impeding tumor progression. The review navigates the labyrinth of cellular and molecular heterogeneity within breast cancer, shedding light on diverse subtypes and their unique vulnerabilities. Notably, we meticulously scrutinize the nuanced efficacy and potential limitations of Paclitaxel across different breast cancer subtypes, delving into the intricate interplay between the drug and the complex cellular microenvironment. Moreover, the review explores cutting-edge trends and advancements, offering insights into novel therapeutic strategies that complement Paclitaxel-based regimens. As a roadmap for researchers and clinicians navigating the microscopic intricacies of breast cancer, this review amalgamates current knowledge, fostering a deeper understanding and paving the way for future therapeutic innovations.

1. Introduction

Breast cancer stands as a formidable challenge to global health, and the incidence rates are increasing in most countries for both sexes necessitating a nuanced understanding of its histological intricacies for precise diagnosis and therapeutic decision-making [1]. The normal histological architecture of the breast sets the stage for comprehending the deviations observed in malignant transformations. The characteristics of histopathology images play an essential role in diagnosing cancer. Cell morphology in histopathology images refers to individual cells' size, shape, and structure of a tissue sample [2].

1. Histological architecture of breast tissue

1.1. Normal histological design

Understanding the normal histological architecture is fundamental for distinguishing pathological changes associated with conditions like breast cancer. The normal histological architecture of breast tissue is complex and dynamic designed to support the essential function of lactation in the female mammary gland. The breast is

composed of several key components, each playing a crucial role in maintaining tissue integrity and function. The ductal system of the mammary gland is made up of branching ducts that drain the terminal secretory lobules. There are 15 to 20 lobes, and a lactiferous duct drain each of them.



Fig. 1. Preliminary diagram of the milk duct system based on research from Hartmann [4], as quoted for Free Use of Breast Anatomy Images by **©Medela AG, Switzerland, 2006.**

These ducts enlarge to form the lactiferous sinus before they open separately into the nipple [3]. The breast ductal system is central to milk transport. It consists of a network of ducts that extend from the nipple to the periphery of the breast. These ducts branch out and terminate in small, grape-like structures called terminal ductal lobular units (TDLUs). TDLUs are the functional units of the breast, where milk production occurs Lobules are glandular structures within the breast that contain clusters of milk-producing cells known as alveoli. These lobules are connected to the ductal system and are responsible for synthesizing and secreting milk during lactation. The stroma is the supportive connective tissue framework that surrounds and encapsulates the ducts and lobules. It consists of fibrous and adipose (fatty) tissue. The stroma provides structural support to the breast and facilitates the movement of nutrients and waste products [5]. Blood vessels supply oxygen and nutrients to the breast tissue, while lymphatic vessels drain excess fluid and play a role in immune surveillance. The lymphatic system is crucial for identifying and removing potentially harmful substances. The breast tissue contains cells with hormone receptors, such as estrogen receptors (ER) and progesterone receptors (PR). These receptors are essential for responding to hormonal signals and regulating various aspects of breast function, including growth and development [6].

1.2. Malignant transformations

Deviations from the normal architecture, as observed through histological examinations, can provide crucial insights into the diagnosis and management of breast diseases. In breast cancer, for example, malignant cells often disrupt the normal architecture, infiltrating the surrounding tissue in distinctive patterns that can be identified through histopathological analysis. In breast cancer, histopathological analysis plays a pivotal role in diagnosing and characterizing the disease. Malignant cells in breast cancer often disrupt the normal architecture of the breast tissue, infiltrating surrounding structures in distinctive patterns. Here are some key aspects of histopathological changes observed in breast cancer:

1.2.1. Invasive Ductal Carcinoma (IDC)

This is the most common type of breast cancer, representing about 80% of cases. In IDC, cancer cells infiltrate the ductal system of the breast, disrupting its normal architecture [7] **(Fig. 2)**. Under the microscope, IDC is characterized by irregularly shaped glands and nests of cancer cells invading the surrounding stroma.



Fig. 2. Human breast with invasive ductal carcinoma (IDC) in an enlarged cross-section of the duct; (A) Ducts, (B) Lobules, (C) Dilated section of duct to hold milk, (D) Nipple, (E) Fat, (F) Pectoralis major muscle, and (G) Chest wall/rib cage.
Enlargement: An invaded duct with (B) ductal cancer cells breaking through (C) the basement membrane. This diagram is provided by Breastcancer.org [8].

1.2.2. Invasive Lobular Carcinoma (ILC)

ILC is another common subtype, accounting for about 10-15% of breast cancers [9, 10]. In ILC, cancer cells infiltrate the lobules of the breast rather than forming a solid mass. The classic "Indian filing" pattern is often observed, where single-file infiltrations of disclosive cells replace the normal lobular architecture [11].

1.2.3. Special Histological Subtypes

There are also special subtypes of breast cancer with distinct histological features. For example, mucinous carcinoma is characterized by the presence of mucin, forming clusters of tumor cells floating in mucin lakes[12]. Tubular carcinoma is defined by well-formed tubules. These subtypes may have different prognostic implications and treatment approaches.

1.2.4. Histological Grading

Histological grading is a system used to evaluate the degree of differentiation and aggressiveness of breast cancer cells [13]. High-grade tumors often exhibit more abnormal cellular features and increased mitotic activity, indicating a more aggressive behavior.

1.2.5. Immunohistochemistry (IHC) and Molecular Markers

IHC is frequently employed to assess the expression of hormone receptors (estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2) in breast cancer [14]. These markers provide valuable information for guiding targeted therapies and predicting treatment response. Histopathological analysis not only aids in diagnosing breast cancer but also provides essential information for determining the stage of the disease, guiding treatment decisions, and predicting patient outcomes

1.3. Various histological subtypes of breast cancer, characteristics, and prognostic implications

Breast cancer is a heterogeneous disease, and various histological subtypes exist, each with distinct characteristics. Understanding these subtypes is crucial for tailoring treatment strategies and predicting patient outcomes. Here are 12 of the key histological types and subtypes of breast cancer **(Table 1)**:

These histological subtypes exhibit diverse clinical behaviors and responses to treatment. The identification, and classification of these subtypes play a crucial role in determining the most appropriate therapeutic approach individually for patients.

1.4. The microscopic features that differentiate invasive ductal carcinoma from invasive lobular carcinoma

Histological microscopic features play a crucial role in differentiating between invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), two common histological subtypes of breast cancer. The distinguishing characteristics are observed at the cellular and architectural levels. Here are the histological microscopic features that differentiate IDC and ILC **(Table 2)**:

1.5. Immunohistochemistry and molecular pathology in breast cancer diagnosis

Immunohistochemistry (IHC) and molecular pathology play integral roles in breast cancer diagnosis, providing valuable insights into the molecular characteristics of tumors. These techniques are essential for classifying subtypes, predicting prognosis, and guiding treatment decisions.

1.5.1. Immunohistochemistry (IHC):

IHC is routinely used to determine the expression of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer cells. Hormone receptor-positive tumors respond well to endocrine therapies [14, 26, 38]. IHC assesses the overexpression of the HER2 protein. HER2-positive tumors may benefit from targeted therapies, such as trastuzumab [39]. IHC staining for Ki-67 provides information about the proliferation rate of cancer cells. High Ki-67 levels are associated with more aggressive tumors [27]. Cytokeratins (e.g., CK7, CK8/18, CK5/6) and epithelial markers help to identify the epithelial origin of cancer cells and differentiate between breast cancer subtypes. Basal-like markers CK5/6 and EGFR are used to identify basal-like or triple-negative breast cancers.

1.5.2. Molecular Pathology

Gene expression profiling such as Oncotype DX, MammaPrint, and Prosigna are molecular assays that assess the expression of multiple genes and help predict the risk of recurrence and the benefit of chemotherapy [40]. BRCA1/BRCA2 mutational analysis and identification of germline mutations can be identified by molecular testing to provide information about hereditary breast cancer risk [41]. Identification of PIK3CA Mutations: Mutations in the PIK3CA gene are associated with certain breast cancer subtypes and may impact treatment decisions [42]. Fluorescence In Situ Hybridization (FISH) is a molecular technique that confirms HER2 amplification in cases where HER2 status is equivocal by IHC [39]. Microsatellite instability (MSI) testing where identification of MSI-High tumors can be relevant in breast cancers associated with Lynch syndrome [43].

Table 1: Twelve histological types and subtypes of breast cancer

Subtype	Characteristics	Prognostic implication	Reference
1- Invasive (Infiltrating) Ductal Carcinoma (IDC)	The most common subtype accounts for approximately 80% of all breast cancers. IDC originates in the milk ducts but invades nearby tissues in the breast. It can present with different histological grades and molecular profiles	Prognosis and treatment decisions are influenced by the histological grade and molecular characteristics of IDC. The prognosis depends on factors such as tumor size, grade, and lymph node involvement. Higher-grade tumors and lymph node positivity are associated with a poorer prognosis	[15, 16]
2- Invasive Lobular Carcinoma (ILC)	Represents about 10-15% of breast cancers. Unlike IDC, ILC originates in the lobules of the breast and tends to have a unique growth pattern characterized by single-file infiltrations of cells. It can be challenging to detect on imaging and may require special diagnostic techniques	Often presents at a more advanced stage and may exhibit unique patterns of metastasis. After accounting for hormone receptor status, patients with IDC had greater lung/pleura and liver involvement, while patients with ILC had a greater propensity to develop ovarian and GI metastases both at first site and overall. Clinicians can use this information to provide more directed screening for metastases; it also adds to the argument that these two variants of breast cancer should be managed as unique diseases	[17]
3- Ductal Carcinoma In Situ (DCIS)	While not invasive, DCIS is a pre-invasive form of breast cancer where abnormal cells are found in the lining of a breast duct but have not invaded nearby tissues. It is often considered a precursor to invasive breast cancer	While non-invasive, DCIS can progress to invasive cancer if untreated. The risk of recurrence and progression varies, and management decisions depend on factors such as grade and margin status	[18]
4- Inflammatory Breast Cancer (IBC)	A rare and aggressive subtype that accounts for a small percentage of breast cancers and is clinically characterized by acute inflammatory changes of the breast. It accounts for about 2.5% of all breast cancers frequently affecting younger age women. It is characterized by redness, swelling, and warmth in the breast, often resembling an infection. IBC tends to grow and spread quickly	Is associated with a poorer prognosis due to its aggressive nature, but advancements in treatment strategies have improved outcomes.	[19, 20]
5- Triple-Negative Breast Cancer (TNBC)	An aggressive clinical phenotype lacks expression of estrogen receptor (ER), and progesterone receptor (PR), and does not overexpress HER2. TNBC is known for its aggressive behavior and limited treatment options compared to other subtypes	Is associated with more aggressive behavior. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and the absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors. It has limited targeted treatment options, and chemotherapy is a primary component of therapy	[21, 22]
6- HER2-Positive	Overexpresses the human epidermal	HER2-positive tumors tend to be more	[23]

Breast Cancer	growth factor receptor 2 (HER2). HER2-positive breast cancers tend to be more aggressive, but targeted therapies such as trastuzumab (Herceptin) have significantly improved outcomes	aggressive, but targeted therapies, such as trastuzumab, have significantly improved outcomes. The introduction of HER2-directed therapies has dramatically influenced the outcome of patients with HER2-positive breast and gastric/gastroesophageal cancers	
7- Luminal A Subtype	Characterized by the expression of estrogen and/or progesterone receptors (ER/PR). These tumors typically have low levels of the proliferation marker Ki-67, indicating a slower rate of cell division. They often express other favorable prognostic markers. Luminal A tumors are less likely to overexpress the human epidermal growth factor receptor 2 (HER2), they were found more constantly in a younger age group. Moreover, they were associated with adverse clinico-histologic parameters like higher grade and nodal metastasis	Associated with a more favorable prognosis compared to other subtypes. They tend to be less aggressive and are more likely to respond to hormone therapies such as tamoxifen or aromatase inhibitors. Luminal A tumors often have a good response to endocrine therapies and a lower risk of recurrence	[24, 25]
8- Luminal B Subtype	Also expresses estrogen and/or progesterone receptors (ER/PR). These tumors, however, have higher levels of Ki-67, indicating a higher rate of cell proliferation. Luminal B tumors may exhibit additional features associated with increased aggressiveness, such as higher histological grade or HER2 overexpression	Are generally associated with a less favorable prognosis compared to Luminal A tumors. They may have a higher risk of recurrence and are more likely to be resistant to hormone therapies alone. Luminal B tumors may benefit from a more aggressive treatment approach, including chemotherapy in addition to endocrine therapy.	[26, 27]
9- Mucinous Carcinoma	A relatively rare subtype of breast cancer accounting for about 2% of all breast carcinomas. According to the latest WHO classification of tumors of the breast, mucinous carcinoma is classified as a special type of breast cancer, characterized by the presence of mucin-producing cells. Mucinous carcinoma tends to have a more favorable prognosis compared to other types of breast cancer	The treatment of mucinous breast carcinoma is based on surgery associated with post-operative hormone therapy in hormone-responsive (ER/PR) tumors. The presence of mucin may influence the tumor's behavior and response to therapy. A recent study recommended axillary staging by sentinel lymph node biopsy and administration of adjuvant radiotherapy and hormone therapy after breast-conservation for mucinous carcinoma	[28-30]
10- Tubular Carcinoma	A distinct, relatively rare low-grade neoplasm, accounts for approximately 1 to 2% of invasive breast cancers. It is composed of well-differentiated tubular structures with open lumina, typically one layer thick surrounded by abundant stroma. Tubular carcinoma is a well-differentiated subtype characterized	Often low-grade and may have a lower risk of recurrence	[31]

	by the presence of well-formed tubules. It is often associated with a good prognosis		
11- Medullary Carcinoma	Is a rare subtype, representing about 5% of breast cancers. Microscopically, tumor cells form sheets or nests with a syncytial appearance. It is often associated with a prominent lymphocytic infiltrate	Is typically high-grade but may have a better prognosis compared to other high-grade tumors	[32, 33]
12- Metaplastic carcinoma	Is a rare and aggressive subtype that includes a variety of different cell types. It is often resistant to conventional therapies	Is often aggressive and its prognosis can vary depending on the specific components present	[34]

Table 2: Histological microscopic features of IDC vs. ILC

Histological microscopic feature	IDC	ILC	Reference
Architectural Features	Irregular Gland Formation: IDC is characterized by irregularly shaped glands or ducts infiltrating the surrounding stroma. These infiltrative patterns may present as solid nests, tubular formations, or cribriform patterns. Desmoplastic Reaction: The stromal response to IDC often includes desmoplastic or fibrotic changes, reflecting the tissue reaction to the invasive tumor	Single-File Infiltration: ILC is characterized by single-file infiltrations of small, uniform cells. This "Indian filing" pattern is distinctive and contrasts with the glandular formations seen in IDC. Lack of Desmoplastic Reaction: Unlike IDC, ILC often lacks a significant desmoplastic response, making it less conspicuous on mammography and physical examination	[15, 31, 35]
Cellular Features	Pleomorphic Cells: IDC cells often exhibit cellular pleomorphism, meaning there is significant variability in the size and shape of the tumor cells. High Mitotic Activity: High mitotic activity is a common feature, indicating a rapid rate of cell division	Disclosive Cells: ILC cells tend to be disclosive, meaning they do not adhere tightly to each other. This property contributes to the single-file pattern seen microscopically. Uniform Cells: ILC cells are typically uniform and small, with minimal cellular pleomorphism	[36, 37]
Immunohistochemical Features	Variable Hormone Receptor Status: IDC can be estrogen receptor (ER) and/or progesterone receptor (PR) positive or negative, contributing to diverse treatment responses. HER2 Expression: IDC may exhibit overexpression of the HER2 protein in some cases	Hormone Receptor Positivity: ILC is characteristically ER and PR positive. Hormone receptor status is a key feature in the diagnosis and management of ILC. HER2 Expression: HER2 expression in ILC is variable; it can be positive or negative	[37, 38]

1.5.3 Significance of Biomarkers and Clinical Implications

Treatment Decision-Making and molecular pathology results guide the choice of targeted therapies, such as hormone therapies, anti-HER2 agents, and chemotherapy. Prognostic stratification can be achieved through molecular profiling that provides additional information for stratifying patients into different risk

categories, influencing treatment intensity and follow-up strategies. Personalized medicine through the integration of molecular information allows for more personalized and targeted treatment approaches, minimizing unnecessary exposure to therapies with limited benefit. Molecular testing helps to assess the risk of recurrence and aids in determining the necessity of adjuvant treatments.

1.5.4 Histological classifications converge with molecular signatures to refine treatment approaches

The convergence of histological classifications with molecular signatures in breast cancer represents a transformative paradigm in oncology. This integration provides a comprehensive understanding of the disease, facilitating more precise diagnosis, prognostication, and tailored therapeutic strategies. The synergy between traditional histopathology and molecular insights refines breast cancer treatment approaches in several key ways. Accurate subtyping and histological classifications, such as ductal or lobular carcinoma, complement molecular subtyping (e.g., Luminal A/B, HER2-enriched, Triple-Negative) provide a dual approach that ensures a more accurate depiction of tumor biology. Prognostic stratification by combining histological features with molecular signatures enhances prognostic accuracy. High-grade histology, for example, may be further refined by incorporating molecular factors, providing a more nuanced understanding of tumor behavior. Molecular signatures can identify predictive biomarkers, such as hormone receptors and HER2 status. Integrating these with histological findings guides targeted therapy decisions, ensuring a tailored approach based on the specific molecular characteristics of the tumor. Treatment response assessment through molecular profiling allows real-time assessment of treatment response. Histological changes, coupled with molecular data, help evaluate the effectiveness of therapies and guide adjustments to the treatment plan. The integration of histological and molecular information aids in comprehensive risk stratification. Patients with a certain histological subtype may have different outcomes based on molecular characteristics, allowing for more personalized risk assessment. Histological classifications identify architectural and cellular features, while molecular signatures (molecular target identification) pinpoint specific genetic alterations. This convergence assists in identifying actionable molecular targets and guiding the selection of targeted therapies. Therapeutic decision-making is increasingly influenced by a combination of histological and molecular information. For example, Luminal A tumors may receive endocrine therapy based on hormone receptor status, while HER2-positive tumors may benefit from anti-HER2 targeted agents [44]. Integrating histopathology and molecular data enhances the design of clinical trials. Patient stratification based on traditional and molecular criteria improves trial outcomes by selecting populations more likely to respond to specific interventions. Molecular techniques, such as circulating tumor DNA analysis, and complement histopathology are beneficial in monitoring minimal residual disease. This aids in detecting early signs of recurrence or treatment resistance. The convergence of histology and molecular signatures aligns with the principles of personalized medicine advances. Treatment plans can be customized based on the unique characteristics of each patient's tumor [45].

1.6. The impact of histology on prognosis and treatment decisions

The microscopic examination of tissue has a profound impact on prognosis and treatment decisions in breast cancer. The histological features of a tumor provide critical information about its behavior, grade, and molecular characteristics, influencing the overall management of the disease. Histological grading has a valuable impact on prognosis by assessing the degree of differentiation and aggressiveness of cancer cells. High-grade tumors, characterized by more abnormal cellular features and increased mitotic activity, are associated with a poorer prognosis. Low-grade tumors, on the other hand, may have a more favorable outlook. Lymph node involvement has a direct impact on prognosis by histologically examining regional lymph nodes to determine the extent of disease spread. The presence of cancer cells in lymph nodes is a powerful prognostic indicator, influencing the likelihood of recurrence and overall survival [46]. Histology contributes to the determination of tumor size and staging which is a crucial factor in treatment planning and prognosis. Larger tumors or those with extensive local invasion may require more aggressive interventions, affecting both prognosis and the choice of treatment modalities [47]. Different histological subtypes, such as invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), have distinct prognostic implications. Treatment decisions, including surgery and adjuvant therapies, may be influenced by the specific subtype. The determination of hormone receptor status (estrogen receptor, progesterone receptor) through histological examination guides the use of endocrine therapies. Hormone receptor-positive

tumors may respond well to hormonal treatments, influencing the choice of adjuvant therapy.

Histology helps determine the HER2 status of the tumor. HER2-positive tumors may benefit from targeted therapies like trastuzumab, which can significantly impact treatment decisions and prognosis. Histological features in neoadjuvant therapy have an impact on treatment decisions through assessing changes in tumor size and histological grade after treatment, which consequently determines decisions for the continuation of therapy or the need for surgical intervention. The histological response of a tumor to preoperative (neoadjuvant) or postoperative (adjuvant) therapies provides insights into treatment efficacy. A favorable response is associated with improved prognosis [48]. Examination of the tumor histological microenvironment, including immune infiltrates, stromal characteristics, and angiogenesis, can influence prognosis. Tumors with a robust immune response may have better responses to certain therapies [49]. Histological information is often integrated with molecular data from multigene assays (e.g., Oncotype DX, MammaPrint) to refine prognosis and guide decisions about the need for chemotherapy [50]. Histological findings serve as the foundation for comprehensive breast cancer management, informing not only prognosis but also the selection of surgical and adjuvant treatment options. The integration of histology with molecular insights continues to advance personalized medicine in breast cancer care, optimizing outcomes for individual patients.

1.7. Paclitaxel chemotherapy in breast cancer

Paclitaxel, a remarkable chemotherapeutic agent, has emerged as a pivotal cornerstone in the treatment paradigm for various malignancies, notably breast cancer. Initially isolated from the Pacific yew tree (*Taxus brevifolia*) in the late 1960s, Paclitaxel's journey from a natural product to a widely utilized anticancer drug has been transformative [51]. Its unique mechanism of action, targeting microtubule dynamics, sets it apart in the landscape of chemotherapy, offering a distinctive approach to impeding cell division and arresting tumor growth**.**

1.7.1. Mechanisms through which Paclitaxel exerts its therapeutic effects

Paclitaxel's mechanism of action as an antimicrotubular agent is intricate and impactful [52]. Its unique properties significantly influence cellular dynamics, particularly during crucial phases of the cell cycle. As a member of the taxane class, Paclitaxel exerts its effects by promoting the assembly of microtubules [51], enhancing the activity of tubulin dimers, and concurrently stabilizing existing microtubules [53]. This dual action of promoting assembly and stabilizing microtubules stands in stark contrast to other antimitotic agents that typically induce depolymerization. The consequence of Paclitaxel's influence on microtubules is profound. By increasing the stability of microtubules, it induces cell cycle arrest at the late G2 phase, preventing the normal progression of cells into mitosis [54]. This arrest impedes cell replication and serves as a key mechanism through which Paclitaxel exerts its anti-proliferative effects. The disrupted cell cycle progression is a critical component of its therapeutic action against rapidly dividing cancer cells. Furthermore, Paclitaxel's impact extends to the mitotic spindle, a vital structure involved in cell division. By distorting mitotic spindles, Paclitaxel disrupts the orderly separation of chromosomes during cell division. This disturbance ultimately leads to chromosome fragmentation, further compromising the ability of cancer cells to divide and proliferate [55].

1.7.2. Paclitaxel and Plasma Membrane Microviscosity

The incorporation of unsaturated fatty acids is known to introduce flexibility and fluidity to the lipid bilayer, thereby influencing membrane properties such as microviscosity. In the context of Paclitaxel treatment, the increased presence of unsaturated fatty acids may contribute to the observed reduction in membrane microviscosity. The significance of these findings lies in the potential link between membrane microviscosity and the cellular response to Paclitaxel [56].

Changes in membrane properties can influence various cellular processes, including signal transduction, membrane trafficking, and cell motility. Therefore, the modulation of membrane microviscosity may play a role in shaping the cellular response to Paclitaxel treatment, potentially influencing the drug's efficacy against tumor cells [57].



Paclitaxel

1.7.3. induction of apoptosis by Paclitaxel

It represents a crucial aspect of its anti-cancer mechanism, particularly in cells where defective cell division has led to the accumulation of abnormalities. Apoptosis, or programmed cell death, is a fundamental process that serves as a protective mechanism to eliminate cells with damaged DNA or other cellular components. In the context of cancer treatment, inducing apoptosis is a desirable outcome as it contributes to the elimination of aberrant cells [58]. Paclitaxel achieves this by its profound impact on microtubules, key structures involved in cell division. As previously discussed, Paclitaxel promotes microtubule assembly and stabilization, disrupting the normal progression of the cell cycle. In the presence of defective cell division, where chromosomes may not segregate correctly or cells may accumulate genetic abnormalities, Paclitaxel-induced disruption of microtubules can trigger signals that lead to apoptosis [59]. Understanding these precise molecular interactions sheds light on why Paclitaxel is particularly effective in treating malignancies characterized by rapid and uncontrolled cell division, such as various forms of breast cancer. The intricate orchestration of microtubule dynamics and cell cycle regulation underscores Paclitaxel's significance as a potent and targeted anticancer agent.

1.7.4. The efficacy and potential limitations of Paclitaxel across different breast cancer subtypes

The efficacy of Paclitaxel in breast cancer treatment is well-established, but its impact can vary across different breast cancer subtypes. Understanding both its strengths and potential limitations in diverse subtypes is crucial for optimizing treatment strategies. Here, we explore the efficacy and potential considerations associated with Paclitaxel across various breast cancer subtypes:

1.7.4.1. HER2-Positive Breast Cancer

Efficacy: Paclitaxel has demonstrated effectiveness in HER2-positive breast cancer, often used in combination with targeted therapies like trastuzumab [60, 61]. The combination regimen enhances the overall response rates and improves outcomes. *Limitations*: Resistance to Paclitaxel may develop over time, necessitating exploration of alternative treatment options. Additionally, managing potential cardiotoxicity when combining Paclitaxel with HER2-targeted therapies is crucial [55].

1.7.4.2. Hormone Receptor-Positive Breast Cancer

Efficacy: Paclitaxel is frequently employed in the treatment of hormone receptor-positive breast cancer, especially in advanced stages. Combinations with hormonal therapies may enhance efficacy [62]. *Limitations*: Resistance may develop, emphasizing the need for exploring sequential or combination therapies. Taxane-associated neuropathy is a potential concern [63].

1.7.4.3. Triple-Negative Breast Cancer (TNBC)

Efficacy: Paclitaxel is a cornerstone in the treatment of TNBC, showcasing notable efficacy in both early and metastatic settings [64]. *Limitations*: Some TNBC cases may exhibit resistance and exploring predictive biomarkers for response becomes crucial. Managing side effects, particularly neuropathy, is a consideration [65].

1.7.4.4. Basal-Like Breast Cancer

Efficacy: Basal-like breast cancers, often overlapping with TNBC, tend to respond well to Paclitaxel. *Limitations*: As with TNBC, managing potential resistance and addressing neuropathy is important [66].

1.7.4.5. Luminal Breast Cancer Subtypes:

Efficacy: Paclitaxel is employed in luminal subtypes, particularly in the advanced or metastatic setting, demonstrating efficacy[67]. *Limitations*: Resistance may emerge, and potential interactions with endocrine therapies need consideration.

1.7.4.6. Inflammatory Breast Cancer (IBC):

Efficacy: Paclitaxel is a key component in the multidisciplinary approach to IBC, often used in neoadjuvant settings [68]. *Limitations*: The aggressive nature of IBC may require additional targeted therapies, and careful monitoring for treatment response is essential.

2. Conclusion

The review showed the importance of exploring the various histological subtypes of breast cancer, spotting light on their distinct characteristics, microscopic features delineating invasive ductal carcinoma, invasive lobular carcinoma, and the related rare subtypes, and the concluded prognostic implications. In addition to diagnostic considerations, the review addressed the impact of histology on prognosis and treatment decisions. Histological grading, nodal involvement, and the tumor microenvironment are indispensable components in breast cancer assessment. Their integration provides a comprehensive understanding of the disease, informs prognostication, and guides the development of personalized and targeted treatment strategies,

ultimately influencing patient outcomes. While Paclitaxel is a valuable chemotherapeutic agent with broad applications in breast cancer, considerations such as potential resistance, side effects, and the need for combination therapies are crucial across different subtypes. Tailoring treatment approaches based on the specific molecular characteristics of each subtype is essential for optimizing the efficacy of Paclitaxel in breast cancer management.

Ethical consideration: The author of this study gave his informed permission.

Conflicts of Interest

No conflicts of interest are disclosed.

Acknowledgments

The author thanks Dr. Taher H. Elwan, Professor of Surgery, Al-Baha University, Faculty of Medicine, KSA, for his valuable advice to initiate this review.

References

[1] Z. Chen, L. Xu, W. Shi, F. Zeng, R. Zhuo, X. Hao, P. Fan, Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017, Breast Cancer Res. Treat. 180(2) (2020) 481-490. https://doi.org/10.1007/s10549-020-05561-1

[2] Z. Zeng, W. Xie, Y. Zhang, Y. Lu, RIC-Unet: An improved neural network based on Unet for nuclei segmentation in histology images, Ieee Access. 7 (2019) 21420-21428. http://doi.org/10.1109/ACCESS.2019.2896920

[3] Y.S. Khan, H. Sajjad, Anatomy, Thorax, Mammary Gland. [Updated 2023 Jul 24]. In. StatPearls [Internet, Treasure Island (FL): StatPearls Publishing, 547666:2023. https://wwwncbinlmnihgov/books/NBK547666 .

[4] P.E. Hartmann, In; Breast Feeding Know-How, Office on Women's Health in the U.S. Department of Health and Human Services. https://webarchive.library.unt.edu/eot2008/20081104211614/http://www.womenshealth.gov/breastfeeding/index.cfm?page=228.

[5] S.K. Biswas, S. Banerjee, G.W. Baker, C-Y. Kuo, I. Chowdhury, The Mammary Gland: Basic Structure and Molecular Signaling during Development, International Journal of Molecular Sciences. 23(7)(2022), 3883. http://doi.org/10.3390/ijms23073883

[6] Z. Li, H. Wei, S. Li, P. Wu, X. Mao, The Role of Progesterone Receptors in Breast Cancer, Drug Des. Devel. Ther. 16 (2022) 305-314. http://doi.org/10.2147%2FDDDT.S336643

[7] O. Metzger-Filho, A.R. Ferreira, R. Jeselsohn, W.T. Barry, D.A. Dillon, J.E. Brock, I. Vaz-Luis, M.E. Hughes, E.P. Winer, N.U. Lin, Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade, Oncologist. 24(7) (2019), e441-e449. http://doi.org/10.1634/theoncologist.2018-0363

[8] DePolo Jamie, Types of breast cancer, Reviewed by 1 medical adviser Jenni Sheng, MD Johns Hopkins University School of Medicine, Baltimore, MD. Breastcancer.org. Last updated on November 6, 2023, at 6:03PM https://www.breastcancer.org/types. Accessed 23 December 2023.

[9] A. Mamtani, T.A. King, Lobular Breast Cancer: Different Disease, Different Algorithms? Surg. Oncol. Clin. N. Am. 27(1) (2018) 81-94. http://doi.org/10.1016/j.soc.2017.07.005

[10] J.A. Mouabbi, A. Hassan, B. Lim, G.N. Hortobagyi, D. Tripathy, R.M. Layman, Invasive lobular carcinoma: an understudied emergent subtype of breast cancer, Breast Cancer Res. Treat. 193(2) (2022) 253-264. http://doi.org/10.1007/s10549-022-06572-w

[11] W.P. Evans, L.J. Warren Burhenne, L. Laurie, K.F. O'Shaughnessy, R.A. Castellino, Invasive lobular carcinoma of the breast: mammographic characteristics and computer-aided detection, Radiology 225(1) (2002) 182-189. http://doi.org/10.1148/radiol.2251011029

[12] M.P. Budzik, M.M. Fudalej, A.M. Badowska-Kozakiewicz, Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type, Sci. Rep. 11(1) (2021) 5770. http://doi.org/10.1038/s41598-021-85309-z

[13] W.A. Oluogun, K.A. Adedokun, M.A. Oyenike, O.A. Adeyeba, Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study, Int. J. Health Sci. (Qassim) 13(4) (2019), 3-9.

[14] D. Hicks, P. Dell'Orto, M. Falzon, K.D. Hoff, Y.Y. Levy, L. McMahon, K. Miller, L. Russo, G. Viale, Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies, Appl. Immunohistochem. Mol. Morphol. 25(5) (2017) 313-319. http://doi.org/10.1097%2FPAI.0000000000000311

[15] J. Makki, Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance, Clin. Med. Insights. Pathol. 8 (2015) 23-31. http://doi.org/10.4137/CPath.S31563

[16] X. Guan, G. Xu, A. Shi, Y. Zou, Y. Zhan, Z. Fan, Y. Dong, Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study, Medicine (Baltimore) 99(50) (2020) e23487. http://doi.org/10.1097%2FMD.0000000000023487

[17] A. Mathew, P.S. Rajagopal, V. Villgran, G.S. Sandhu, R.C. Jankowitz, Jacob M, Rosenzweig M, Oesterreich S, Brufsky A: Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe Frauenheilkd, 77(6) (2017), 660-666. http://doi.org/10.1055/s-0043-109374

[18] A. Van Cleef, S. Altintas, M. Huizing, K. Papadimitriou, P. Van Dam, W. Tjalma, Current view on ductal carcinoma in situ and importance of the margin thresholds: A review, Facts Views Vis. Obgyn. 6(4) (2014), 210-218. PMCID: PMC4286860 PMID: 25593696

[19] S. Dawood, X. Lei, R. Dent, S. Gupta, B. Sirohi, J.Cortes, M. Cristofanilli, T. Buchholz, A.M. Gonzalez-Angulo, Survival of women with inflammatory breast cancer: a large population-based study, Ann. Oncol. 25(6) (2014), 1143-1151.http://doi.org/10.1093/annonc/mdu121

[20] M. Di Bonito, M. Cantile, G. Botti, Pathological and molecular characteristics of inflammatory breast cancer, Translational Cancer Research. (2019) S449-S456. http://doi.org/10.21037/tcr.2019.03.24

[21] S.K. Pal, B.H. Childs, M. Pegram, Triple-negative breast cancer: unmet medical needs, Breast Cancer Res. Treat. 125(3) (2011) 627-636. http://doi.org/10.1007/s10549-010-1293-1

[22] H. Yao, G. He, S. Yan, C. Chen, L. Song, T.J. Rosol, X. Deng, Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 8(1) (2017) 1913-1924. http://doi.org/10.18632/oncotarget.12284

[23] N. Iqbal, N. Iqbal, Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications, Mol. Biol. Int. (2014) 852748. http://doi.org/10.1155/2014/852748

[24] M.J. Higgins, V. Stearns, Understanding resistance to tamoxifen in hormone receptor-positive breast cancer, Clin. Chem. 55(8) (2009) 1453-1455. http://doi.org/10.1373/clinchem.2009.125377

[25] A.A. Hashmi, S. Aijaz, S.M. Khan, R. Mahboob, M. Irfan, N.I. Zafar, M. Nisar, M. Siddiqui, M.M. Edhi, N. Faridi et al., Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients, World Journal of Surgical Oncology. 16(1) (2018) 1. http://doi.org/10.1186/s12957-017-1299-9

[26] L. Braun, F. Mietzsch, P. Seibold, A. Schneeweiss, P. Schirmacher, J. Chang-Claude, H. Peter Sinn, S. Aulmann, Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss, Modern Pathology. 26(9) (2013) 1161-1171. http://doi.org/10.1038/modpathol.2013.60

[27] Z. Inic, M. Zegarac, M. Inic, I. Markovic, Z. Kozomara, I. Djurisic, I. Inic, G. Pupic, S. Jancic, Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information, Clin. Med. Insights Oncol. 8 (2014) 107-111. http://doi.org/10.4137/cmo.s18006

[28] C.R. Barkley, J.A. Ligibel, J.S. Wong, S. Lipsitz, B.L. Smith, M. Golshan, Mucinous breast carcinoma: a large contemporary series, Am. J. Surg. 196(4) (2008) 549-551. http://doi.org/10.1016/j.amjsurg.2008.06.013

[29] E. Marrazzo, F. Frusone, F. Milana, A. Sagona, W. Gatzemeier, E. Barbieri, A. Bottini, G. Canavese, A.O. Rubino, M.G. Eboli et al., Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis, Breast 49 (2020) 87-92. DOI: 10.1016/j.breast.2019.11.002

[30] F. Limaiem, F. Ahmad, Mucinous Breast Carcinoma. [Updated Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan- Available from: https://wwwncbinlmnihgov/books/NBK538334/ 2023.

[31] N.S. Goldstein, L.L. Kestin, F.A. Vicini, Refined morphologic criteria for tubular carcinoma to retain its favorable outcome status in contemporary breast carcinoma patients, Am. J. Clin. Pathol. 122(5) (2004) 728-739. http://doi.org/10.1309/9fep-8u8a-ugqn-gy3v

[32] J.H. Eichhorn, Medullary carcinoma, provocative now as then, Semin. Diagn. Pathol. 21(1) (2004) 65-73. http://doi.org/10.1053/j.semdp.2003.10.005

[33] W.D. Foulkes, I.E. Smith, J.S. Reis-Filho, Triple-negative breast cancer, N. Engl. J. Med. 363(20) (2010) 1938-1948. http://doi.org/10.1056/nejmra1001389

[34] A. Papatheodoridi, E. Papamattheou, S. Marinopoulos, I. Ntanasis-Stathopoulos, C. Dimitrakakis, A. Giannos, M. Kaparelou, M. Liontos, M.A. Dimopoulos, F. Zagouri, Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature, Med. Sci. (Basel) 11(2) (2023) 35. http://doi.org/10.3390/medsci11020035

[35] G. Cserni, Histological type and typing of breast carcinomas and the WHO classification changes over time, Pathologica 112(1) (2020) 25-41. http://doi.org/10.32074/1591-951x-1-20

[36] D.C. Sgroi, Preinvasive breast cancer, Annu. Rev. Pathol. 5 (2010) 193-221.

[37] G. Sflomos, K. Schipper, T. Koorman, A. Fitzpatrick, S. Oesterreich, A.V. Lee, J. Jonkers, V.G. Brunton, M. Christgen, C. Isacke et al., Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions, Cancers. 13(21) (2021).

[38] S.K. Sohail, R. Sarfraz, M. Imran, M. Kamran, S. Qamar, Estrogen and Progesterone Receptor Expression in Breast Carcinoma and Its Association With Clinicopathological Variables Among the Pakistani Population, Cureus. 12(8) (2020) e9751. http://doi.org/10.7759/cureus.9751

[39] B. Zhao, Y. Wang, H. Xu, Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China, Int. J. Clin. Exp. Pathol. 10(10) (2017) 10459-10466.

[40] A. Smith, K. Farrah, CADTH Rapid Response Reports. In: Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review. edn. Ottawa (ON), Canadian Agency for Drugs and Technologies in Health
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health. (2019)

[41] N. Petrucelli, M.B. Daly, T. Pal, BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer, (1998) Sep 4 [updated 2023 Sep 21]. In: Adam M.P., Feldman J., Mirzaa G.M., Pagon R.A., Wallace S.E., Bean L.J.H., Gripp K.W., Amemiya A., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. PMID: 20301425. (2023) Available from: https://www.ncbi.nlm.nih.gov/books/NBK124. 2023.

[42] K. Reinhardt, K. Stückrath, C. Hartung, S. Kaufhold, C. Uleer, V. Hanf, T. Lantzsch, S. Peschel, J. John, M. Pöhler et al., PIK3CA-mutations in breast cancer, Breast Cancer Res. Treat. 196(3) (2022) 483-493. http://doi.org/10.1007/s10549-022-06637-w

[43] M. Amato, R. Franco, G. Facchini, R. Addeo, F. Ciardiello, M. Berretta, G. Vita, A. Sgambato, S. Pignata, M. Caraglia et al., Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers, International journal of molecular sciences. 23(15) (2022). http://doi.org/10.3390/ijms23158726

[44] A. Höller, B.D. Nguyen-Sträuli, H. Frauchiger-Heuer, A. Ring, "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?", Breast Cancer (Dove Med Press). 15 (2023) 525-540. http://doi.org/10.2147%2FBCTT.S340741

[45] L.H. Goetz, N.J. Schork, Personalized medicine: motivation, challenges, and progress, Fertil. Steril. 109(6) (2018) 952-963. http://doi.org/10.1016/j.fertnstert.2018.05.006

[46] F. Tonellotto, A. Bergmann, K. de Souza Abrahão, S.S. de Aguiar, M.A. Bello, L.C.S. Thuler, Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer, Eur. J. Breast Health. 15(2) (2019) 76-84. http://doi.org/10.5152%2Fejbh.2019.4414

[47] K.H. Allison, Prognostic and predictive parameters in breast pathology: a pathologist's primer, Modern Pathology. 34 (2021), 94-106. http://doi.org/10.1038/s41379-020-00704-7

[48] H. Wang, X. Mao, Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer, Drug Des. Devel. Ther. 14 (2020) 2423-2433. DOI: 10.2147/dddt.s253961

[49] J.J. Li, J.Y. Tsang, G.M. Tse, Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment, Cancers 13(16) (2021). Doi:10.3390/cancers13164233

[50] F. Cognetti, L. Biganzoli, S. De Placido, L. Del Mastro, R. Masetti, G. Naso, G. Pruneri, D. Santini, C.A. Tondini, C. Tinterri et al., Multigene tests for breast cancer: the physician's perspective, Oncotarget. 12(9) (2021) 936- 947. http://doi.org/10.18632/oncotarget.27948

[51] A.O. Awosika, M.C. Farrar, T.F. Jacobs, Paclitaxel. (2023) Nov 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725602.Available from: https://wwwncbinlmnihgov/books/NBK536917/ 2023 Nov 18].

[52] D.N. Kampan, M. Madondo, O. McNally, M. Quinn, M. Plebanski, Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer, BioMed Research International. 2015(2015) 1-21. https://doi.org/10.1155/2015/413076

[53] A.E. Prota, D. Lucena-Agell, Y. Ma, J. Estevez-Gallego, S. Li, K. Bargsten, F. Josa-Prado, K.H. Altmann, N. Gaillard, S. Kamimura et al., Structural insight into the stabilization of microtubules by taxanes, eLife. 12 (2023). https://doi.org/10.7554/eLife.84791

[54] S. Asnaashari, E. Amjad, B. Sokouti, Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review, Cancer cell international 23(1) (2023) 211. DOI:10.1186/s12935-023-03052-z

[55] M. Sousa-Pimenta, L.M. Estevinho, A. Szopa, M. Basit, K. Khan, M. Armaghan, M. Ibrayeva, E. Sönmez Gürer, D. Calina, C. Hano, J. Sharifi-Rad, Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel, Front. Pharmacol. 14 (2023) 1157306. https://doi.org/10.3389/fphar.2023.1157306

[56] L. Shimolina, A. Gulin, A. Khlynova, N. Ignatova, I.Druzhkova, M. Gubina, E. Zagaynova, M.K. Kuimova, M. Shirmanova, Effects of Paclitaxel on Plasma Membrane Microviscosity and Lipid Composition in Cancer Cells, International journal of molecular sciences. 24(15) (2023). https://doi.org/10.3390/ijms241512186

[57] X. Di, X. Gao, L. Peng, J. Ai, X. Jin, S. Qi, H. Li, K. Wang, D. Luo, Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets, Signal transduction and targeted therapy. 8(1) (2023) 282. https://doi.org/10.1038/s41392-023-01501-9

[58] J. Škubník, V. Svobodová Pavlíčková, T. Ruml, S. Rimpelová, Autophagy in cancer resistance to paclitaxel: Development of combination strategies, Biomedicine & Pharmacotherapy. 161 (2023) 114458. https://doi.org/10.1016/j.biopha.2023.114458

[59] X. Wang, B. Gigant, X. Zheng, Q. Chen, Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies, MedComm – Oncology. 2(3) (2023) e46. https://doi.org/10.1002/mog2.46

[60] M. Tapia, C. Hernando, M.T. Martínez, O. Burgués, C. Tebar-Sánchez, A. Lameirinhas, A. Ágreda-Roca, S. Torres-Ruiz, I. Garrido-Cano, A. Lluch et al., Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies, Cancers. 15(18) (2023) 4522. https://doi.org/10.3390/cancers15184522

[61] S.M. Tolaney, P. Tarantino, N. Graham, N. Tayob, L. Parè, G. Villacampa, C.T. Dang, D.A.Yardley, B. Moy, P.K. Marcom et al., Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial, The Lancet Oncology. 24(3) (2023) 273-285. https://doi.org/10.1016/S1470-2045(23)00051-7

[62] D.T. Le, L.T. Bui, C.V. Nguyen, K.H. Do, G.L. Tran, T.A. Do, Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam, Oncology and therapy. 11(3) (2023) 327-341. doi: 10.1007/s40487-023-00233-8

[63] N. Stache, S. Bohn, K. Sperlich, C. George, K. Winter, F. Schaub, H.V. Do, M. Röhlig, K.M. Reichert, S. Allgeier et al., Taxane-Induced Neuropathy and Its Ocular Effects-A Longitudinal Follow-up Study in Breast Cancer Patients, Cancers. 15(9) (2023) 2444. https://doi.org/10.3390/cancers15092444

[64] I. Nederlof, L. Voorwerk, M. Kok, Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer, Clinical cancer research: an official journal of the American Association for Cancer Research. 29(13) (2023) 2362-2370. https://doi.org/10.1158/1078-0432.CCR-22-0701

[65] W. Gao, L. Sun, J. Gai, Y. Cao, S. Zhang, Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis, PLoS ONE 19(1) (2024) e0297260. https://doi.org/10.1371/journal.pone.0297260

[66] J. Watson, T. Wang, K-L. Ho, Y. Feng, T. Mahawan, K.K. Dobbin, S. Zhao, Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs, Breast Cancer Research. 25(1) (2023) 114. DOI:10.1186/s13058-023-01705-5

[67] X. Yang, A. Smirnov, O.C. Buonomo, A. Mauriello, Y. Shi, J. Bischof, J. Woodsmith, P. Bove, V. Rovella, M. Scimeca et al., A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency, Cell Death Discovery. 9(1) (2023) 365. https://doi.org/10.1038/s41420-023-01650-4

[68] P. Bahrami, H. Moayeri, G. Moradi, E. Nouri, Y. Moradi, Systematic Review and Meta-Analysis of Treatment Effects on Survival in Patients with Inflammatory Breast Cancer, Asian Pacific journal of cancer prevention: APJCP. 24(10) (2023) 3335-3343. doi: 10.31557/APJCP.2023.24.10.3335